• Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Ala767_Val769dupAlaSerVal (c.2300_2308dup) (A767_V769dupASV); ClinVar=VCV000177678; Zygosity=Heterozygous (PubMed=33355298).
  

PubMed=29686424; DOI=10.1038/s41591-018-0007-9; PMCID=PMC5964608
Robichaux J.P., Elamin Y.Y., Tan Z., Carter B.W., Zhang S.-X., Liu S.-W., Li S., Chen T., Poteete A., Estrada-Bernal A., Le A.T., Truini A., Nilsson M.B., Sun H.-Y., Roarty E., Goldberg S.B., Brahmer J.R., Altan M., Lu C., Papadimitrakopoulou V., Politi K., Doebele R.C., Wong K.-K., Heymach J.V.
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Nat. Med. 24:638-646(2018)

PubMed=33355298; DOI=10.1158/1078-0432.CCR-20-3555; PMCID=PMC7926264
Estrada-Bernal A., Le A.T., Doak A.E., Tirunagaru V.G., Silva S., Bull M.R., Smaill J.B., Patterson A.V., Kim C., Liu S.V., Doebele R.C.
Tarloxotinib is a hypoxia-activated pan-HER kinase inhibitor active against a broad range of HER-family oncogenes.
Clin. Cancer Res. 27:1463-1475(2021)